<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1117">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05146609</url>
  </required_header>
  <id_info>
    <org_study_id>TGSS_EXCAD_AP</org_study_id>
    <nct_id>NCT05146609</nct_id>
  </id_info>
  <brief_title>Acceptance of Hepatitis C Screening by Self-testing in High Risk and General Population</brief_title>
  <official_title>Acceptance of Hepatitis C Screening by Self-testing in High Risk and General Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of La Laguna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of La Laguna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the study is to evaluate the acceptance and viability of self-testing&#xD;
      using dried blood spot (DBS) testing assisted by center of origin or referral hospital, as a&#xD;
      strategy for screening for hepatitis C virus (HCV) in high risk population (ex-users of drug&#xD;
      dependence centers) compared to the general population assisted by primary care centers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized clinical trial involving patients who between 2013 and 2017 have&#xD;
      contacted the drug dependence center and patients from general population.&#xD;
&#xD;
      After selecting those who do not meet any exclusion criteria, a letter will be sent to them&#xD;
      inviting them to participate in this study. This letter will contain the study information&#xD;
      sheet and informed consent, and a self-testing kit with an explanatory leaflet so that each&#xD;
      person can carry out the test in a simple and easy way.&#xD;
&#xD;
      The main purpose of the study is to evaluate the acceptance and viability of self-testing&#xD;
      using dried blood spot (DBS) testing, to study whether support improves participation and to&#xD;
      identify predictors of participation.&#xD;
&#xD;
      For the present study, assuming an increase of 18% participation (from 18% to 28% offering&#xD;
      support by the patient's referral center, and based on a previous study in our environment of&#xD;
      self-testing in the general population), taking into account a power of 80%, alpha error of&#xD;
      5%, and losses of 20%, will require 346 patients per group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acceptance of the intervention</measure>
    <time_frame>12 months</time_frame>
    <description>Overall screening rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viability</measure>
    <time_frame>12 months</time_frame>
    <description>The investigators will measure and report the amount of DBS received from the participants, taking into account the group to which the participants belong.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participation</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants by sending their DBS and different possible factors associated to a higher rate of participation.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1384</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>HR-HOSPITAL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to the strategy HR-HOSPITAL, who are high risk population (HR), will receive an invitation letter for HCV screening with DBS to be performed by themselves or at the referral hospital.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HR-DDP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to the strategy HR-DDP, who are high risk population, will receive an invitation letter for HCV screening with DBS to be performed by themselves or at the drug dependence center (DDP) the participants used to attend.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GP-HOSPITAL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to the strategy GP-HOSPITAL, who are general population (GP), will receive an invitation letter for HCV screening with DBS to be performed by themselves or at the referral hospital.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GP-PCC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to the strategy GP-PCC, who are general population (GP), will receive an invitation letter for HCV screening with DBS to be performed by themselves or at the primary care center (PCC) to be performed by the general practitioner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Screening HCV. HR-HOSPITAL</intervention_name>
    <description>Screening HCV in high risk population by themselves or at referral hospital.</description>
    <arm_group_label>HR-HOSPITAL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Screening HCV. HR-DDP</intervention_name>
    <description>Screening HCV in high risk population by themselves or at drug dependence center.</description>
    <arm_group_label>HR-DDP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Screening HCV. GP-HOSPITAL</intervention_name>
    <description>Screening HCV in general population by themselves or at referral hospital.</description>
    <arm_group_label>GP-HOSPITAL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Screening HCV. GP-PCC</intervention_name>
    <description>Screening HCV in general population by themselves or at primary care center.</description>
    <arm_group_label>GP-PCC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  All subjects who have contacted a drug dependence center between 2013 and 2017, as&#xD;
             well as patients from a group of a primary care center.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patient's refusal to participate in the study.&#xD;
&#xD;
          -  Negative HCV serology or viral load in the last year.&#xD;
&#xD;
          -  Death.&#xD;
&#xD;
          -  Belonging to another health area&#xD;
&#xD;
          -  Not having the patient's address in the hospital's computer system.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Manuel Hernandez-Guerra, MD</last_name>
    <phone>+34922678559</phone>
    <email>mhernand@ull.edu.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Santa Cruz De Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Manuel Hernandez-Guerra, MD</last_name>
      <phone>+34922678559</phone>
      <email>mhernand@ull.edu.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014 Feb;60(2):392-420. doi: 10.1016/j.jhep.2013.11.003. Epub 2013 Dec 9. Erratum in: J Hepatol. 2014 Jul;61(1):183-4.</citation>
    <PMID>24331294</PMID>
  </reference>
  <reference>
    <citation>Baumert TF, JÃ¼hling F, Ono A, Hoshida Y. Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med. 2017 Mar 14;15(1):52. doi: 10.1186/s12916-017-0815-7. Review.</citation>
    <PMID>28288626</PMID>
  </reference>
  <reference>
    <citation>Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014 Nov;61(1 Suppl):S58-68. doi: 10.1016/j.jhep.2014.07.012. Epub 2014 Nov 3. Review.</citation>
    <PMID>25443346</PMID>
  </reference>
  <reference>
    <citation>Sarin SK, Kumar M. Natural history of HCV infection. Hepatol Int. 2012 Oct;6(4):684-95. doi: 10.1007/s12072-012-9355-6. Epub 2012 Mar 9.</citation>
    <PMID>26201520</PMID>
  </reference>
  <reference>
    <citation>Buti M, DomÃ­nguez-HernÃ¡ndez R, Casado MÃ, Sabater E, Esteban R. Healthcare value of implementing hepatitis C screening in the adult general population in Spain. PLoS One. 2018 Nov 28;13(11):e0208036. doi: 10.1371/journal.pone.0208036. eCollection 2018.</citation>
    <PMID>30485377</PMID>
  </reference>
  <reference>
    <citation>Juanbeltz R, PÃ©rez-GarcÃ­a A, Aguinaga A, MartÃ­nez-Baz I, Casado I, Burgui C, GoÃ±i-Esarte S, RepÃ¡raz J, Zozaya JM, San Miguel R, Ezpeleta C, Castilla J; EIPT-VHC Study Group. Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain. PLoS One. 2018 Dec 4;13(12):e0208554. doi: 10.1371/journal.pone.0208554. eCollection 2018.</citation>
    <PMID>30513107</PMID>
  </reference>
  <reference>
    <citation>Morales-Arraez D, HernÃ¡ndez-Guerra M. Electronic Alerts as a Simple Method for Amplifying the Yield of Hepatitis C Virus Infection Screening and Diagnosis. Am J Gastroenterol. 2020 Jan;115(1):9-12. doi: 10.14309/ajg.0000000000000487. Review.</citation>
    <PMID>31833860</PMID>
  </reference>
  <reference>
    <citation>Fitz JG. Hepatology after Hepatitis C. Dig Dis. 2016;34(5):603-6. doi: 10.1159/000445276. Epub 2016 Jun 22.</citation>
    <PMID>27332966</PMID>
  </reference>
  <reference>
    <citation>Crespo J, Albillos A, Buti M, Calleja JL, GarcÃ­a-Samaniego J, HernÃ¡ndez-Guerra M, Serrano T, Turnes J, AcÃ­n E, Berenguer J, Berenguer M, Colom J, FernÃ¡ndez I, FernÃ¡ndez RodrÃ­guez C, Forns X, GarcÃ­a F, Rafael Granados, Lazarus JV, Molero JM, Molina E, PÃ©rez Escanilla F, Pineda JA, RodrÃ­guez M, Romero M, Roncero C, Saiz de la Hoya P, SÃ¡nchez AntolÃ­n G. Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). Gastroenterol Hepatol. 2019 Nov;42(9):579-592. doi: 10.1016/j.gastrohep.2019.09.002. Epub 2019 Oct 5. English, Spanish.</citation>
    <PMID>31594683</PMID>
  </reference>
  <reference>
    <citation>Morales-Arraez D, HernÃ¡ndez-Bustabad A, Medina-Alonso MJ, Santiago-GutiÃ©rrez LG, GarcÃ­a-Gil S, Diaz-Flores F, PÃ©rez-PÃ©rez V, Nazco J, Fernandez de Rota Martin P, GutiÃ©rrez F, HernÃ¡ndez-Guerra M. Telemedicine and decentralized hepatitis C treatment as a strategy to enhance retention in care among people attending drug treatment centres. Int J Drug Policy. 2021 Aug;94:103235. doi: 10.1016/j.drugpo.2021.103235. Epub 2021 Apr 7.</citation>
    <PMID>33838399</PMID>
  </reference>
  <reference>
    <citation>Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, Lane HC, Memish Z, Oh MD, Sall AA, Schuchat A, Ungchusak K, Wieler LH; WHO Strategic and Technical Advisory Group for Infectious Hazards. COVID-19: towards controlling of a pandemic. Lancet. 2020 Mar 28;395(10229):1015-1018. doi: 10.1016/S0140-6736(20)30673-5. Epub 2020 Mar 17.</citation>
    <PMID>32197103</PMID>
  </reference>
  <reference>
    <citation>Blach S, Kondili LA, Aghemo A, Cai Z, Dugan E, Estes C, Gamkrelidze I, Ma S, Pawlotsky JM, Razavi-Shearer D, Razavi H, Waked I, Zeuzem S, Craxi A. Impact of COVID-19 on global HCV elimination efforts. J Hepatol. 2021 Jan;74(1):31-36. doi: 10.1016/j.jhep.2020.07.042. Epub 2020 Aug 7.</citation>
    <PMID>32777322</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of La Laguna</investigator_affiliation>
    <investigator_full_name>Manuel Hernandez-Guerra, MD</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

